Edition:
United States

Profile: Halozyme Therapeutics Inc (HALO.O)

HALO.O on Nasdaq

16.42USD
19 Sep 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$16.42
Open
--
Day's High
--
Day's Low
--
Volume
1,102
Avg. Vol
1,309,088
52-wk High
$17.55
52-wk Low
$8.18

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Company Address

Halozyme Therapeutics Inc

11388 Sorrento Valley Rd
SAN DIEGO   CA   92121-1345
P: +1858.7948889
F: +1302.6555049

Company Web Links